Analyzing ARS Pharmaceuticals (SPRY) and Its Peers
by Danessa Lincoln · The Markets DailyARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) is one of 896 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare ARS Pharmaceuticals to similar businesses based on the strength of its institutional ownership, valuation, analyst recommendations, risk, profitability, earnings and dividends.
Risk and Volatility
ARS Pharmaceuticals has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500. Comparatively, ARS Pharmaceuticals’ competitors have a beta of -3.71, suggesting that their average stock price is 471% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings and target prices for ARS Pharmaceuticals and its competitors, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ARS Pharmaceuticals | 1 | 1 | 4 | 0 | 2.50 |
| ARS Pharmaceuticals Competitors | 7798 | 13888 | 25778 | 1037 | 2.41 |
ARS Pharmaceuticals presently has a consensus target price of $23.33, indicating a potential upside of 736.32%. As a group, “Pharmaceuticals” companies have a potential upside of 25.57%. Given ARS Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts plainly believe ARS Pharmaceuticals is more favorable than its competitors.
Profitability
This table compares ARS Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ARS Pharmaceuticals | -163.64% | -318.81% | -69.34% |
| ARS Pharmaceuticals Competitors | -2,380.38% | -217.94% | -15.54% |
Institutional and Insider Ownership
68.2% of ARS Pharmaceuticals shares are owned by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 33.8% of ARS Pharmaceuticals shares are owned by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares ARS Pharmaceuticals and its competitors gross revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| ARS Pharmaceuticals | $84.28 million | -$171.30 million | -1.28 |
| ARS Pharmaceuticals Competitors | $3.56 billion | $3.19 billion | 555.10 |
ARS Pharmaceuticals’ competitors have higher revenue and earnings than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Summary
ARS Pharmaceuticals beats its competitors on 7 of the 13 factors compared.
About ARS Pharmaceuticals
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.